<div id="readability-page-1"><div> <div> , /PRNewswire/ -- The law firm of Kessler Topaz Meltzer &amp; Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed against DexCom, Inc. (&#34;DexCom&#34;) (NASDAQ: DXCM) on behalf of those who purchased or otherwise acquired DexCom securities between January 8, 2024, and September 17, 2025, inclusive (the &#34;Class Period&#34;). The lead plaintiff deadline is December 26, 2025. CONTACT KESSLER TOPAZ MELTZER &amp; CHECK, LLP: If you suffered DexCom losses, you may CLICK HERE or copy and paste the following link into your browser: https://www.ktmc.com/new-cases/dexcom-inc-1?utm_source=PR_Newswire&amp;mktm=PR You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. DEFENDANTS' ALLEGED MISCONDUCT: The complaints allege that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) DexCom had made material design changes to its G6 and G7 continuous glucose monitoring systems that were unauthorized by the FDA; (2) the foregoing design changes rendered the G6 and G7 less reliable than their prior iterations, presenting a material health risk to users relying on those devices for accurate glucose readings; (3) DexCom's purported enhancements to the G7, as well as the device's reliability, accuracy, and functionality, were overstated; (4) DexCom downplayed the true scope and severity of the issues and health risks posed by adulterated G7 devices; (5) all the foregoing subjected DexCom to an increased risk of heightened regulatory scrutiny and enforcement action, as well as significant legal, reputational, and financial harm; and (6) as a result, Defendants' public statements were materially false and/or misleading at all relevant times. Please CLICK HERE to view our video or copy and paste this link into your browser: https://youtube.com/shorts/ToTm4-K0ODs?feature=share THE LEAD PLAINTIFF PROCESS: DexCom investors may, no later than December 26, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer &amp; Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Kessler Topaz Meltzer &amp; Check, LLP encourages DexCom investors who have suffered significant losses to contact the firm directly to acquire more information. CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: https://www.ktmc.com/new-cases/dexcom-inc-1?utm_source=PR_Newswire&amp;mktm=PR ABOUT KESSLER TOPAZ MELTZER &amp; CHECK, LLP: Kessler Topaz Meltzer &amp; Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. For more information about Kessler Topaz Meltzer &amp; Check, LLP, please visit www.ktmc.com. CONTACT: Kessler Topaz Meltzer &amp; Check, LLP Jonathan Naji, Esq. (484) 270-1453 280 King of Prussia Road Radnor, PA 19087 [email protected] May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes. SOURCE Kessler Topaz Meltzer &amp; Check, LLP <img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjE0Jk5ld3NJdGVtSWQ9REM0Mzk1MiZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMTQxMTI0UFJfTkVXU19VU1BSX19fX19EQzQzOTUy?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjE0Jk5ld3NJdGVtSWQ9REM0Mzk1MiZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMTQxMTI0UFJfTkVXU19VU1BSX19fX19EQzQzOTUy"/></div> </div></div>

DXCM

Kessler Topaz Meltzer & Check, LLP has filed securities class action lawsuits against DexCom, Inc. for alleged securities fraud. The lawsuit covers those who acquired DexCom securities between January 8, 2024, and September 17, 2025. Allegations include unauthorized design changes to glucose monitoring systems, misleading statements, and increased regulatory scrutiny. The lead plaintiff deadline is December 26, 2025. Investors who suffered losses are encouraged to contact the law firm for more information.

prnewswire

DexCom

11:24 ET
			
			
				DXCM CLASS ACTION ALERT:  Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc. Shareholders of Securities Fraud Class Action Lawsuit

11:24 ET DXCM CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc. Shareholders of Securities Fraud Class Action Lawsuit